US2016096812A1PendingUtilityA1

Treatment of cancer/inhibition of metastasis

45
Assignee: DJAMGOZ MUSTAFA BILGIN ALIPriority: Oct 13, 2010Filed: Oct 13, 2015Published: Apr 7, 2016
Est. expiryOct 13, 2030(~4.2 yrs left)· nominal 20-yr term from priority
Inventors:Mustafa Bilgin Ali Djamgoz
A61P 43/00A61P 15/00A61P 35/04A61P 13/08C07D 295/15A61K 31/495C07D 241/04A61K 31/167A61K 31/19A61K 31/428A61K 31/138C07D 277/82A61K 31/00A61K 31/4458
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Substances and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole.

Claims

exact text as granted — not AI-modified
1 . Ranolazine for reducing or preventing metastatic behaviour in VGSC expressing cancer. 
     
     
         2 . Ranolazine according to  claim 1 , wherein the cancer is breast cancer. 
     
     
         3 . Ranolazine according to  claim 1 , wherein the cancer is prostate cancer. 
     
     
         4 . Riluzole for reducing or preventing metastatic behaviour in VGSC expressing cancer without directly killing the cancer cells. 
     
     
         5 . Riluzole according to  claim 4 , wherein the cancer is breast cancer. 
     
     
         6 . Riluzole according to  claim 4 , wherein the cancer is prostate cancer. 
     
     
         7 . A substance for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. 
     
     
         8 . A substance according to  claim 7 , having said effect in breast cancer. 
     
     
         9 . A substance according to  claim 7 , having said effect in prostate cancer. 
     
     
         10 . A substance according to  claim 7 , having said effect without killing the cells. 
     
     
         11 . A substance according to  claim 7 , having said effect without substantially affecting proliferation. 
     
     
         12 . Ranolazine according to  claim 1 , in a dosage level corresponding to the range 1 μmol to 10 μmol. 
     
     
         13 . Riluzole according to  claim 4 , in a dosage level corresponding to the range 1 μmol of 10 μmol. 
     
     
         14 . A method of reducing or preventing metastatic behaviour in VGSC expressing cancer comprising administering ranolazine. 
     
     
         15 . A method according to  claim 14 , wherein the cancer is breast cancer. 
     
     
         16 . A method according to  claim 14 , wherein the cancer is prostate cancer. 
     
     
         17 . A method of reducing or preventing metastatic behaviour in VGSC expressing cancer, comprising administering riluzole without directly killing the cancer cells. 
     
     
         18 . A method according to  claim 17 , wherein the cancer is breast cancer. 
     
     
         19 . A method according to  claim 17 , wherein the cancer is prostate cancer. 
     
     
         20 . A method of reducing or preventing metastatic behaviour in VGSC expressing cancer by administering a drug having the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. 
     
     
         21 . A method according to  claim 20 , wherein the cancer is breast cancer. 
     
     
         22 . A method according to  claim 20 , wherein the cancer is prostate cancer. 
     
     
         23 . A method according to  claim 20 , carried out without killing the cells. 
     
     
         24 . A method according to  claim 20 , carried out without substantially affecting proliferation. 
     
     
         25 . The method according to  claim 13 , wherein the ranolazine is administered in a dosage level corresponding to the range 1 μmol to 10 μmol. 
     
     
         26 . A method according to  claim 17 , wherein the riluzole is administered in a dosage level corresponding to the range 1 μmol of 10 μmol.

Join the waitlist — get patent alerts

Track US2016096812A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.